Houston gained 43,217 residents from July 2023 to July 2024. Photo via Getty Images

Houston saw the second-highest population increase in the United States in 2024, according to the U.S. Census Bureau.

The new population report revealed Houston gained 43,217 residents from July 2023 to July 2024, bringing the city's population to 2,390,125.

Houston hung on to its ranking as the fourth largest city in the country and joined 11 other Southern cities that saw the largest numeric population gains in 2024, the report added.

Elsewhere in Texas, Fort Worth is now home to more than 1 million residents, surpassing Austin as the 11th largest city in the U.S. Fort Worth had the fifth-highest numeric increase in population, adding 23,442 residents during that same time frame to bring the city's total population to 1,008,106 residents.

Dallas retained its No. 9 spot on the list of the 15 most populous cities in the U.S. The city gained more than 23,000 residents during the one-year period, bringing its population to 1,326,087 people in 2024.


Austin slipped two spots and now ranks as the 13th largest city after adding more than 13,000 residents to bring the Texas Capital's population to 993,588.

San Antonio gained 23,945 residents — the fourth-highest increase nationwide — and was the only other city besides Houston to have a higher numerical growth rate than Fort Worth during the one-year period.

Fastest-growing U.S. cities
Princeton, a North Texas suburb of Dallas, topped the charts as the No. 1 fastest-growing U.S. city in 2024. The Census Bureau says the city's population has more than doubled in the last five years to more than 37,000 residents.

Fulshear, 34 miles from downtown Houston, has continued its rapid expansion as the second-fastest growing city. The suburb grew nearly 27 percent since the previous year, and its population rose to 54,629 residents as of July 2024.

Five additional Texas cities made the list of fastest-growing U.S. cities:

  • Celina, near Dallas (No. 4) with 18.2 percent growth (51,661 total population)
  • Anna, near Dallas (No. 5) with 14.6 percent growth (31,986 total population)
  • Fate, near Dallas (No. 8) with 11.4 percent growth (27,467 total population)
  • Melissa, near Dallas (No. 11) with 10 percent growth (26,194 total population)
  • Hutto, near Austin (No. 13) with 9.4 percent growth (42,661 total population)

The Austin suburb of Georgetown's growth has continued to slow down since 2023, and it no longer appears in the list of fastest-growing cities. However, it did surpass 100,000 residents in 2024. San Angelo, a small city in West Texas, also surpassed the 100,000-population threshold.

Most populous U.S. cities in 2024
New York City maintained its stronghold as the biggest in America in 2024, boasting a population of nearly 8.5 million residents. Los Angeles and Chicago also retained second and third place, with respective populations of nearly 3.88 million and more than 2.7 million residents.

"Cities in the Northeast that had experienced population declines in 2023 are now experiencing significant population growth, on average," said Crystal Delbé, a statistician in the Census Bureau’s Population Division. "In fact, cities of all sizes, in all regions, showed faster growth and larger gains than in 2023, except for small cities in the South, whose average population growth rate remained the same."

The 15 populous U.S. cities as of July 1, 2024 were:

  • No. 1 – New York, New York (8.48 million)
  • No. 2 – Los Angeles, California (3.88 million)
  • No. 3 – Chicago, Illinois (2.72 million)
  • No. 4 – Houston, Texas (2.39 million)
  • No. 5 – Phoenix, Arizona (1.67 million)
  • No. 6 – Philadelphia, Pennsylvania (1.57 million)
  • No. 7 – San Antonio, Texas (1.53 million)
  • No. 8 – San Diego, California (1.4 million)
  • No. 9 – Dallas, Texas (1.33 million)
  • No. 10 – Jacksonville, Florida (1 million)
  • No. 11 – Fort Worth, Texas (1 million)
  • No. 12 – San Jose, California (997,368)
  • No. 13 – Austin, Texas (993,588)
  • No. 14 – Charlotte, North Carolina (943,476)
  • No. 15 – Columbus, Ohio (933,263)
---

A version of this article originally appeared on CultureMap.com.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.